Lukas Bunse
@lukasbunse.bsky.social
Neurologist and Immunologist at University Heidelberg and DKFZ with a focus on immunotherapy and cellular therapy of brain tumors and CNS autoimmunity
Reposted by Lukas Bunse
The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/...
Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.
Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.
The immunology of brain tumors
The cellular and molecular determinants of the antigenicity of brain tumors and the immunosuppressive brain tumor microenvironment are reviewed.
www.science.org
October 4, 2025 at 10:49 AM
The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/...
Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.
Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.
Reposted by Lukas Bunse
Our CIMT coverage is out!
👉 Go to bit.ly/3SUQCOX to read a summary of select talks. #CIMT2025 Featured are: @ki.se @unileiden.bsky.social @ethz.ch @niaidnews.bsky.social @dkfz.bsky.social @lukasbunse.bsky.social @biontech.bsky.social
👉 Go to bit.ly/3SUQCOX to read a summary of select talks. #CIMT2025 Featured are: @ki.se @unileiden.bsky.social @ethz.ch @niaidnews.bsky.social @dkfz.bsky.social @lukasbunse.bsky.social @biontech.bsky.social
May 28, 2025 at 8:00 PM
Our CIMT coverage is out!
👉 Go to bit.ly/3SUQCOX to read a summary of select talks. #CIMT2025 Featured are: @ki.se @unileiden.bsky.social @ethz.ch @niaidnews.bsky.social @dkfz.bsky.social @lukasbunse.bsky.social @biontech.bsky.social
👉 Go to bit.ly/3SUQCOX to read a summary of select talks. #CIMT2025 Featured are: @ki.se @unileiden.bsky.social @ethz.ch @niaidnews.bsky.social @dkfz.bsky.social @lukasbunse.bsky.social @biontech.bsky.social
Reposted by Lukas Bunse
Herzlichen Glückwunsch:
🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social
🏆️ Dr. Lukas Bunse
@lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6
🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social
🏆️ Dr. Lukas Bunse
@lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6
March 28, 2025 at 11:33 AM
Herzlichen Glückwunsch:
🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social
🏆️ Dr. Lukas Bunse
@lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6
🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social
🏆️ Dr. Lukas Bunse
@lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6
Reposted by Lukas Bunse
Huge congrats @lukasbunse.bsky.social, so well deserved, fantastic achievement.
@hlsalliance.bsky.social @cn-hd.bsky.social @neurooncologyhd.bsky.social @mctneuroscience.bsky.social @platten-lab.bsky.social
@hlsalliance.bsky.social @cn-hd.bsky.social @neurooncologyhd.bsky.social @mctneuroscience.bsky.social @platten-lab.bsky.social
Herzlichen Glückwunsch:
🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social
🏆️ Dr. Lukas Bunse
@lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6
🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social
🏆️ Dr. Lukas Bunse
@lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6
March 28, 2025 at 11:54 AM
Huge congrats @lukasbunse.bsky.social, so well deserved, fantastic achievement.
@hlsalliance.bsky.social @cn-hd.bsky.social @neurooncologyhd.bsky.social @mctneuroscience.bsky.social @platten-lab.bsky.social
@hlsalliance.bsky.social @cn-hd.bsky.social @neurooncologyhd.bsky.social @mctneuroscience.bsky.social @platten-lab.bsky.social
Reposted by Lukas Bunse
PTPRZ1 was upregulated in GBM samples and was associated with cell stemness (GSC score). [...] bit.ly/416M1wV @lukasbunse.bsky.social
February 25, 2025 at 1:00 PM
PTPRZ1 was upregulated in GBM samples and was associated with cell stemness (GSC score). [...] bit.ly/416M1wV @lukasbunse.bsky.social
Reposted by Lukas Bunse
Congratulations to David for being a finalist for the YPIC #proteomics Fund!
We are happy to support his application at the Immunopeptidomics Platform HI-TRON and hope the fund will make this breakthrough project possible in collab with David from @lukasbunse.bsky.social lab at @dkfz.bsky.social
We are happy to support his application at the Immunopeptidomics Platform HI-TRON and hope the fund will make this breakthrough project possible in collab with David from @lukasbunse.bsky.social lab at @dkfz.bsky.social
Meet YPIC Student Proteomics Fund finalist David Palmero
Cantón!
David is a biotechnologist by training who specialized in cancer research during his master’s studies and is now pursuing his PhD at DKFZ-German Cancer Research Center.
Cantón!
David is a biotechnologist by training who specialized in cancer research during his master’s studies and is now pursuing his PhD at DKFZ-German Cancer Research Center.
February 21, 2025 at 5:55 PM
Congratulations to David for being a finalist for the YPIC #proteomics Fund!
We are happy to support his application at the Immunopeptidomics Platform HI-TRON and hope the fund will make this breakthrough project possible in collab with David from @lukasbunse.bsky.social lab at @dkfz.bsky.social
We are happy to support his application at the Immunopeptidomics Platform HI-TRON and hope the fund will make this breakthrough project possible in collab with David from @lukasbunse.bsky.social lab at @dkfz.bsky.social
Reposted by Lukas Bunse
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen
www.nature.com/articles/s41...
@lukasbunse.bsky.social @naturecomms.bsky.social
www.nature.com/articles/s41...
@lukasbunse.bsky.social @naturecomms.bsky.social
February 2, 2025 at 5:37 PM
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen
www.nature.com/articles/s41...
@lukasbunse.bsky.social @naturecomms.bsky.social
www.nature.com/articles/s41...
@lukasbunse.bsky.social @naturecomms.bsky.social
1/2 Super excited to see this finally out @naturecomms.bsky.social ! We developed an off-the-shelf T cell receptor T cell therapy for patients with glioblastoma from a peptide vaccinated patient. Looking very much forward to its translation within DKTK supported by HI-TRON!
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen - Nature Communications
Vaccination in glioblastomas does lead to the emergence of tumour-antigen-specific T cells but T cell dysfunction, poor tumour infiltration and persistence hinder efficient tumour killing. Here author...
www.nature.com
February 2, 2025 at 9:08 PM
1/2 Super excited to see this finally out @naturecomms.bsky.social ! We developed an off-the-shelf T cell receptor T cell therapy for patients with glioblastoma from a peptide vaccinated patient. Looking very much forward to its translation within DKTK supported by HI-TRON!
Reposted by Lukas Bunse
Great fun to write this perspective with @lukasbunse.bsky.social @platten-lab.bsky.social @dkfz-iic.bsky.social @dkfz.bsky.social on a highly interesting study by the Bardeesy Lab. This study provides additional mechanistic rationale to combine IDH inhibitors with T cell activating therapies.
A recent study unpicks a key immune-mediated mechanism of mutant IDH–blocking drugs such as vorasidenib in the treatment of IDH-mutant glioma. Learn more in a new Clinical Implications of Basic Research article: nej.md/4f3dIMf
#MedSky
#MedSky
Heating Up IDH-Mutant Gliomas | NEJM
A recent study unpicks a key immune-mediated mechanism of mutant IDH–blocking drugs such as vorasidenib in the treatment of IDH-mutant glioma.
nej.md
December 11, 2024 at 5:45 PM
Great fun to write this perspective with @lukasbunse.bsky.social @platten-lab.bsky.social @dkfz-iic.bsky.social @dkfz.bsky.social on a highly interesting study by the Bardeesy Lab. This study provides additional mechanistic rationale to combine IDH inhibitors with T cell activating therapies.
Reposted by Lukas Bunse
Could not be any prouder. Stellar work, fantastic lecture - day to remember. Welcome to the faculty @lukasbunse.bsky.social.
Today we congratulate @lukasbunse.bsky.social for his successful dissertation and his inaugural lecture at umm Mannheim. Congratulations!!
November 29, 2024 at 6:58 PM
Could not be any prouder. Stellar work, fantastic lecture - day to remember. Welcome to the faculty @lukasbunse.bsky.social.